[1] S. Mehta, et al., “Predictive and Prognostic Molecular Markers for Cancer Medicine,” Therapeutic Advances in Medical Oncology, Vol. 2, No. 2, 2010, pp. 125-148. http://dx.doi.org/10.1177/175 8834009360519
[2] A. W. Opstal-van Winden, et al., “Searching for Early Breast Cancer Biomarkers by Serum Protein Profiling of Pre-Diagnostic Serum; a Nested Case-Control Study,” BMC Cancer, Vol. 11, 2011, p. 381. http://dx.doi.org/10.1186/1471-2407-11-381
[3] S. Y. Park, et al., “Promoter CpG Island Hypermethylation during Breast Cancer Progression,” Virchows Arch, Vol. 458, No. 1, 2011, pp. 73-84. http://dx.doi.org/10.1007/s00428-010-1013-6
[4] P. Taneja, et al., “Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance,” Clinical Medicine Insights: Oncology, Vol. 4, 2010, pp. 15-34.
[5] M. T. Weigel and M. Dowsett, “Current and Emerging Biomarkers in Breast Cancer: Prognosis and Prediction,” Endocrine-Related Cancer, Vol. 17, No. 4, 2010, pp. R245-R262. http://dx.doi.org/10. 1677/ERC-10-0136
[6] F. Zhang, et al., “Recursive SVM Biomarker Selection for Early Detection of Breast Cancer in Peripheral Blood,” BMC Medical Genomics, Vol. 6, Suppl. 1, 2013, p. S4. http://dx.doi.org/10.1186/ 1755-8794-6-S1-S4
[7] K. D. Cole, H. J. He and L. Wang, “Breast Cancer Biomarker Measurements and Standards,” PROTEOMICSClinical Applications, Vol. 7, No. 1-2, 2013, pp. 17-29. http://dx.doi.org/10.1002/prca. 201200075
[8] A. Bedirian, et al., “Pleckstrin Homology and Phosphotyrosine-Binding Domain-Dependent Membrane Association and Tyrosine Phosphorylation of Dok-4, an Inhibitory Adapter Molecule Expressed in Epithelial Cells,” Journal of Biological Chemistry, Vol. 279, 2004, pp. 19335-19349. http://dx.doi.org/ 10.1074/jbc.M310689200
[9] A. H. Berger, et al., “Identification of DOK Genes as Lung Tumor Suppressors,” Nature Genetics, Vol. 42, 2010, pp. 216-223. http://dx.doi.org/10.1038/ng.527
[10] C. H. An, et al., “Mutational and Expressional Analysis of a Haploinsufficient Tumor Suppressor Gene DOK2 in Gastric and Colorectal Cancers,” APMIS, Vol. 119, No. 8, 2011, pp. 562-564.
http://dx.doi.org/10.1111/j.1600-0463.2011.02749.x
[11] H. Miyagaki, et al., “DOK2 as a Marker of Poor Prognosis of Patients with Gastric Adenocarcinoma after Curative Resection,” Annals of Surgical Oncology, Vol. 19, No. 5, 2012, pp. 1560-1567.
http://dx.doi.org/10.1245/s10434-011-2157-6
[12] R. Mashima, et al., “Mice Lacking Dok-1, Dok-2, and Dok-3 Succumb to Aggressive Histiocytic Sarcoma,” Laboratory Investigation, Vol. 90, 2010, pp. 1357-1364. http://dx.doi.org/10.1038/ labinvest.2010.121
[13] R. J. Crowder, et al., “Dok-6, a Novel p62 Dok Family Member, Promotes Ret-Mediated Neurite Outgrowth,” Journal of Biological Chemistry, Vol. 279, 2004, pp. 42072-42081. http://dx.doi.org/10. 1074/jbc.M403726200
[14] J. Grimm, et al., “Novel p62dok Family Members, dok-4 and dok-5, Are Substrates of the c-Ret Receptor Tyrosine Kinase and Mediate Neuronal Differentiation,” Journal of Cell Biology, Vol. 154, No. 2, 2001, pp. 345-354. http://dx.doi.org/10.1083/jcb.200102032
[15] J. Cossins, et al., “The Spectrum of Mutations That Underlie the Neuromuscular Junction Synaptopathy in DOK7 Congenital Myasthenic Syndrome,” Human Molecular Genetics, Vol. 21, No. 17, 2012, pp. 3765-3775. http://dx.doi.org/10.1093/hmg/dds198
[16] E. Bergamin, et al., “The Cytoplasmic Adaptor Protein Dok7 Activates the Receptor Tyrosine Kinase MuSK via Dimerization,” Molecular Cell, Vol. 39, No. 1, 2010, pp. 100-109. http://dx.doi.org/10.1016/ j.molcel.2010.06.007
[17] A. Inoue, et al., “Dok-7 Activates the Muscle Receptor Kinase MuSK and Shapes Synapse Formation,” Science Signaling, Vol. 2, No. 59, 2009, p. ra7. http://dx.doi.org/10.1126/scisignal.2000113
[18] A. Klein, et al., “DOK7 Congenital Myasthenic Syndrome in Childhood: Early Diagnostic Clues in 23 Children,” Neuromuscular Disorders, Vol. 23, No. 11, 2013, pp. 883-891. http://dx.doi.org/10.1016/ j.nmd.2013.06.002
[19] J. S. Muller, et al., “Phenotypical Spectrum of DOK7 Mutations in Congenital Myasthenic Syndromes,” Brain, Vol. 130, No. 6, 2007, pp. 1497-1506. http://dx.doi.org/10.1093/brain/awm068
[20] K. Okada, et al., “The Muscle Protein Dok-7 Is Essential for Neuromuscular Synaptogenesis,” Science, Vol. 312, No. 5781, 2006, pp. 1802-1805. http://dx.doi.org/10.1126/science.1127142
[21] T. Cheusova, et al., “Casein Kinase 2-Dependent Serine Phosphorylation of MuSK Regulates Acetylcholine Receptor Aggregation at the Neuromuscular Junction,” Genes & Development, Vol. 20, 2006, pp. 1800-1816. http://dx.doi.org/10.1101/gad.375206
[22] D. J. Glass, et al., “Agrin Acts via a MuSK Receptor Complex,” Cell, Vol. 85, No. 4, 1996, pp. 513-523. http://dx.doi.org/10.1016/S0092-8674(00)81252-0
[23] S. Klein-Scory, et al., “Immunoscreening of the Extracellular Proteome of Colorectal Cancer Cells,” BMC Cancer, Vol. 10, 2010, p. 70. http://dx.doi.org/10.1186/1471-2407-10-70
[24] D. Drygin, et al., “Protein Kinase CK2 Modulates IL-6 Expression in Inflammatory Breast Cancer,” Biochemical and Biophysical Research Communications, Vol. 415, No. 1, 2011, pp. 163-167. http://dx.doi.org/10.1016/j.bbrc.2011.10.046
[25] H. Heyn, et al., “DNA Methylation Profiling in Breast Cancer Discordant Identical Twins Identifies DOK7 as Novel Epigenetic Biomarker,” Carcinogenesis, Vol. 34, No. 1, 2013, pp. 102-108. http://dx.doi.org/10.1093/carcin/bgs321
[26] M. Esteller, “Epigenetics in Cancer,” New England Journal of Medicine, Vol. 358, 2008, pp. 1148-1159. http://dx.doi.org/10.1056/NEJMra072067
[27] Y. Huang, et al., “Epigenetics in Breast Cancer: What’s New?” Breast Cancer Research, Vol. 13, 2011, p. 225. http://dx.doi.org/10.1186/bcr2925
[28] S. Sharma, T. K. Kelly and P. A. Jones, “Epigenetics in Cancer,” Carcinogenesis, Vol. 31, No. 1, 2010, pp. 27-36. http://dx.doi.org/10.1093/carcin/bgp220
[29] J. F. Costello, et al., “Aberrant CpG-Island Methylation Has Non-Random and Tumour-Type-Specific Patterns,” Nature Genetics, Vol. 24, 2000, pp. 132-138. http://dx.doi.org/10.1038/72785
[30] J. Hamuro, et al., “The Transcription Factor Sp1 Plays a Crucial Role in dok-7 Gene Expression,” Biochemical and Biophysical Research Communications, Vol. 408, No. 2, 2011, pp. 293-299.
http://dx.doi.org/10.1016/j.bbrc.2011.04.020
[31] S. Lu and M. C. Archer, “Sp1 Coordinately Regulates de Novo Lipogenesis and Proliferation in Cancer Cells,” International Journal of Cancer, Vol. 126, No. 2, 2010, pp. 416-425. http://dx.doi.org/10.1002/ ijc.24761
[32] S. U. Mertens-Talcott, et al., “Betulinic Acid Decreases ER-Negative Breast Cancer Cell Growth in Vitro and in Vivo: Role of Sp Transcription Factors and microRNA-27a:ZBTB10,” Molecular Carcinogenesis, Vol. 52, No. 8, 2013, pp. 591-602. http://dx.doi.org/10.1002/mc.21893
[33] X. B. Wang, et al., “Expression and Prognostic Value of Transcriptional Factor sp1 in Breast Cancer,” Chinese Journal of Cancer, Vol. 26, No. 9, 2007, pp. 996-1000.
[34] M. Wei, et al., “Stat6 Cooperates with Sp1 in Controlling Breast Cancer Cell Proliferation by Modulating the Expression of p21 (Cip1/WAF1) and p27 (Kip1),” Cellular Oncology, Vol. 36, No. 1, 2013, pp. 79-93. http://dx.doi.org/10.1007/s13402-012-0115-3
[35] X. Yang, et al., “HSF1 and Sp1 Are Involved in the Regulation of FUT4 Gene Expression and Cell Proliferation in Breast Cancer Cells,” Journal of Cellular Biochemistry, Vol. 115, No. 1, 2014, pp. 168-178.
[36] L. Yue, et al., “The Oncoprotein HBXIP Activates Transcriptional Coregulatory Protein LMO4 via Sp1 to Promote Proliferation of Breast Cancer Cells,” Carcinogenesis, Vol. 34, No. 4, 2013, pp. 927-935. http://dx.doi.org/10.1093/carcin/bgs399
[37] Y. Zhang, et al., “The Oncoprotein HBXIP Upregulates PDGFB via Activating Transcription Factor Sp1 to Promote the Proliferation of Breast Cancer Cells,” Biochemical and Biophysical Research Communications, Vol. 434, No. 2, 2013, pp. 305-310. http://dx.doi.org/10.1016/j.bbrc.2013.02.123
[38] W. Sasi, et al., “Higher Expression Levels of SOCS 1,3,4,7 Are Associated with Earlier Tumour Stage and Better Clinical Outcome in Human Breast Cancer,” BMC Cancer, Vol. 10, 2010, p. 178. http://dx.doi.org/10.1186/1471-2407-10-178
[39] W. Al Sarakbi, et al., “The mRNA Expression of SETD2 in Human Breast Cancer: Correlation with ClinicoPathological Parameters,” BMC Cancer, Vol. 9, 2009, p. 290. http://dx.doi.org/10.1186/1471-2407-9-290
[40] W. G. Jiang, et al., “Prognostic Value of rho GTPases and rho Guanine Nucleotide Dissociation Inhibitors in Human Breast Cancers,” Clinical Cancer Research, Vol. 9, No. 17, 2003, pp. 6432-6440.
[41] T. Nakagawa, et al., “Decreased Expression of SOCS-3 mRNA in Breast Cancer with Lymph Node Metastasis,” Oncology Reports, Vol. 19, No. 1, 2008, pp. 33-39.
[42] Z. Dogusan, et al., “Expression of SOCS Genes in Normal and Leukemic Human Leukocytes Stimulated by Prolactin, Growth Hormone and Cytokines,” Journal of Neuroimmunology, Vol. 109, No. 1, 2000, pp. 34-39. http://dx.doi.org/10.1016/S0165-5728(00)00300-3
[43] A. Saulnier, et al., “Inactivation of the Putative Suppressor Gene DOK1 by Promoter Hypermethylation in Primary Human Cancers,” International Journal of Cancer, Vol. 130, No. 11, 2012, pp. 2484-2494. http://dx.doi.org/10.1002/ijc.26299
[44] A. Ben Ammar, et al., “A Mutation Causes MuSK Reduced Sensitivity to Agrin and Congenital Myasthenia,” PLoS One, Vol. 8, 2013, Article ID: e53826. http://dx.doi.org/10.1371/annotation/ 3ff2b918-c83c-4c6f-a2e2-4d91294ec92f
[45] W. C. Chang and J. J. Hung, “Functional Role of Post-Translational Modifications of Sp1 in Tumorigenesis,” Journal of Biomedical Science, Vol. 19, 2012, p. 94. http://dx.doi.org/10.1186/1423-0127-19-94